Pluristem Therapeutics (NASDAQ: PSTI) is one of 214 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Pluristem Therapeutics to similar businesses based on the strength of its analyst recommendations, risk, valuation, profitability, institutional ownership, dividends and earnings.

Risk and Volatility

Pluristem Therapeutics has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500. Comparatively, Pluristem Therapeutics’ competitors have a beta of 1.50, indicating that their average share price is 50% more volatile than the S&P 500.

Institutional and Insider Ownership

4.5% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 46.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.0% of Pluristem Therapeutics shares are held by company insiders. Comparatively, 13.9% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Pluristem Therapeutics and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluristem Therapeutics 0 0 4 0 3.00
Pluristem Therapeutics Competitors 490 2383 6476 122 2.66

Pluristem Therapeutics currently has a consensus price target of $4.38, indicating a potential upside of 165.15%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.10%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Pluristem Therapeutics is more favorable than its competitors.

Earnings & Valuation

This table compares Pluristem Therapeutics and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Pluristem Therapeutics $2.85 million -$27.81 million -5.16
Pluristem Therapeutics Competitors $220.75 million -$39.68 million -64.06

Pluristem Therapeutics’ competitors have higher revenue, but lower earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Pluristem Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pluristem Therapeutics N/A -89.81% -72.46%
Pluristem Therapeutics Competitors -4,204.56% -120.13% -45.19%

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company’s products include PLX-PAD and PLX R18. The Company’s PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company’s PLX products are administered using a standard needle and syringe. The Company’s PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women’s health diseases.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.